611 (Recombinant Humanized Anti-Interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for 611 (Recombinant Humanized Anti-Interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody), covering 2026-01-15 to 2026-01-15. Get the full timeline:
Most recent: Clinical Trial Update: Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis [Phase 3]